During the past decade, Georgia Eye Partners conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Georgia Eye Partners" are "Dry Eye Disease (DED)" (1 trials) and "Glaucoma" (1 trials). Many other conditions were trialed in "Georgia Eye Partners" in a lesser frequency.

Most popular intervention types in "Georgia Eye Partners" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "011516X (New Artificial Tear Formulation)" (1 trials), "REFRESH PLUS®" (1 trials), "Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%" (1 trials) and "Systane Ultra Multidose" (1 trials). Other intervention names were less common.

The vast majority of trials in "Georgia Eye Partners" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Georgia Eye Partners". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Georgia Eye Partners, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Georgia Eye Partners, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".